FDA Approves Subcutaneous Rituximab for Blood Cancers

June 22, 2017 – The FDA has approved subcutaneous rituximab for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). Genentech, the manufacturer of the treatment, explained in a statement that the novel co-formulation includes the identical monoclonal … (leggi tutto)